Clinical Trial Update: NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update for NUC-1031 in platinum-resistant ovarian cancer; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• NUC-1031

Snippet

Sponsor: NuCana plc | Conditions: Ovarian Cancer | Phase 2 | Status: TERMINATED | Results posted: 2021-02-21